Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920968 | 0.87 | MAPK14 (0.60) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL4482442 | 0.83 | — | — | |
| SCHEMBL4458202 | 0.82 | MAPK14 (0.58) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL4469245 | 0.82 | MAPK14 (0.56) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL4471008 | 0.82 | MAPK14 (0.60) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL14572143 | 0.80 | — | — | |
| SCHEMBL14561227 | 0.79 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL3520464 | 0.78 | CDK2 (0.67) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL4462590 | 0.76 | MAPK14 (0.54) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL4462595 | 0.76 | MAPK14 (0.54) | MAPK14CCNA2CDK2CSNK1ECDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504501-B2 | Antiprotozoal imidazopyridine compounds | MERIAL LIMITED (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504501-B2 | Antiprotozoal imidazopyridine compounds | MERIAL LIMITED (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504501-B2 | Antiprotozoal imidazopyridine compounds | MERIAL LIMITED (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060178358-A1 | Antiprotozoal imidazopyridine compounds | MERIAL, INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178358-A1 | Antiprotozoal imidazopyridine compounds | PNPO, PIR, TYMP | MAPK14 3045/4885CCNA2 942/4885CDK2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.